Shukla Sath's Form 4 filing
Spero Therapeutics, Inc. (SPRO) · filed Aug 30, 2023
- Accession no.
- 0000950170-23-045441
- Filed
- Aug 30, 2023
- Trade date
- Aug 28-29, 2023
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions and 0 derivative transactions. Open-market sales total $7.75K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Shukla SathCIK 0001782817 | Director, Officer (CEO and President) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 28, 2023 | Common Stock | SSaleDisposed | −1,854 | $1.26 | −$2,336.04 | 576,663 | Direct | |
| Aug 29, 2023 | Common Stock | SSaleDisposed | −4,163 | $1.30 | −$5,411.9 | 572,500 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.